Moreover, it was found that TNFAIP1 overexpression was related to an unfavorable prognosis in breast cancer [53] and TNFAIP1 has been suggested as a valid therapeutic target for the treatment of cancer with paclitaxel resistance, since it confers acquired resistance to this potent antitumor agent in various human malignancies [42]. The gene discussed is TNFAIP1; the disease is breast carcinoma.